GenMark Diagnostics, Inc, a molecular diagnostics company, develops and commercializes molecular tests based on its proprietary eSensor electrochemical detection technology. It provides ePlex instrument and respiratory pathogen panel, which integrates automated nucleic acid extraction and amplification with its eSensor detection technology to enable operators using ePlex system to place patient sample directly into its test cartridge and obtain results.
Read More…
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Phone760-448-4300
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$70.76 million
Profitability
Miscellaneous
Employees477
Next Earnings Date11/4/2019 (Estimated)
OptionableOptionable
GenMark Diagnostics (NASDAQ:GNMK) Frequently Asked Questions
What is GenMark Diagnostics' stock symbol?
GenMark Diagnostics trades on the NASDAQ under the ticker symbol "GNMK."
How were GenMark Diagnostics' earnings last quarter?
GenMark Diagnostics, Inc (NASDAQ:GNMK) announced its quarterly earnings data on Monday, August, 5th. The medical equipment provider reported ($0.23) earnings per share for the quarter, missing analysts' consensus estimates of ($0.21) by $0.02. The medical equipment provider had revenue of $18.37 million for the quarter, compared to the consensus estimate of $17.92 million. GenMark Diagnostics had a negative net margin of 63.86% and a negative return on equity of 167.54%. View GenMark Diagnostics' Earnings History.
When is GenMark Diagnostics' next earnings date?
What guidance has GenMark Diagnostics issued on next quarter's earnings?
GenMark Diagnostics issued an update on its FY 2019 earnings guidance on Monday, August, 5th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $85-90 million, compared to the consensus revenue estimate of $87.32 million.
What price target have analysts set for GNMK?
4 Wall Street analysts have issued 12-month target prices for GenMark Diagnostics' stock. Their predictions range from $7.00 to $12.00. On average, they expect GenMark Diagnostics' stock price to reach $9.67 in the next year. This suggests a possible upside of 85.9% from the stock's current price. View Analyst Price Targets for GenMark Diagnostics.
What is the consensus analysts' recommendation for GenMark Diagnostics?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GenMark Diagnostics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for GenMark Diagnostics.
What are Wall Street analysts saying about GenMark Diagnostics stock?
Here are some recent quotes from research analysts about GenMark Diagnostics stock:
- 1. According to Zacks Investment Research, "GenMark Diagnostics, Inc. is a molecular diagnostics company focused on developing and commercializing its proprietary eSensor(R) detection technology. The eSensor® XT-8 system is the second generation in GenMark Dx's eSensor® platform, utilizing electrochemical detection technology to detect nucleic acids on a microarray. The XT-8 System enables multiplex detection of DNA and RNA targets. The Company has developed four diagnostic tests for use with its XT-8 System. Its Cystic Fibrosis Genotyping Test, which detects pre-conception risks of cystic fibrosis, and its Warfarin Sensitivity Test, which determines an individual's ability to metabolize the oral anticoagulant warfarin, have received FDA clearance. It has also developed a Respiratory Viral Panel Test, which detects the presence of major respiratory viruses, and a Thrombosis Risk Test, which detects an individual's increased risk of blood clots. GenMark Diagnostics, Inc. is based in Pasadena, California. " (10/8/2019)
- 2. Canaccord Genuity analysts commented, "We are positive on the hire of the role of SVP of Sales, adding to the company’s management team. GenMark is well positioned to execute this year as the sales force now has the new trio" of blood culture ID panels to sell. We reiterate our BUY rating and $10 price target. Q1 was a slight beat – impressive given tough Y/Y comp. Q1 revs of $21.5M (+4% Y/ Y) beat our $20.7M (flat $20.9M, which we view as solid particularly given a very difficult comp due to last year’s record influenza season. GNMK placed 39 net ePlex instruments, above our 34E. LPS of ($0.21) matched us and was in line with Street’s ($0.20). OPEX of $16.8M (+12% Y/Y) was consistent with our $16.2M. Reiterates 2019 revenue/placement guide." (5/1/2019)
- 3. Needham & Company LLC analysts commented, "GNMK’s 4Q18 revenue was consistent with its preannouncement while its EPS missed consensus. Management provided 2019 revenue guidance that was above consensus at the mid-point and ePlex placement guidance that was above our estimate at the mid-point. GNMK placed 42 ePlex systems in 4Q18, down from 45 in 3Q18 but above our estimate of 39. We believe the 4Q18 results provide further evidence that ePlex is gaining momentum while GNMK works out its manufacturing growing pains. We think an expanding test menu should help drive ePlex placements and utilization 2019 and we reiterate our Buy rating." (2/22/2019)
Has GenMark Diagnostics been receiving favorable news coverage?
News headlines about GNMK stock have trended very negative this week, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. GenMark Diagnostics earned a media sentiment score of -3.3 on InfoTrie's scale. They also gave media headlines about the medical equipment provider a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the company's share price in the next several days. View News Stories for GenMark Diagnostics.
Who are some of GenMark Diagnostics' key competitors?
Some companies that are related to GenMark Diagnostics include Silk Road Medical (SILK), AtriCure (ATRC), Orthofix Medical (OFIX), Luminex (LMNX), Cryolife (CRY), Shockwave Medical (SWAV), Tactile Systems Technology (TCMD), Anika Therapeutics (ANIK), Cerus (CERS), LeMaitre Vascular (LMAT), SurModics (SRDX), Axonics Modulation Technologies (AXNX), MiMedx Group (MDXG), Antares Pharma (ATRS) and AngioDynamics (ANGO).
What other stocks do shareholders of GenMark Diagnostics own?
Who are GenMark Diagnostics' key executives?
GenMark Diagnostics' management team includes the folowing people:
- Mr. Hany Massarany, CEO, Pres & Director (Age 58)
- Mr. Scott Mendel, Chief Operating Officer (Age 52)
- Mr. Michael Gleeson, Sr. VP of Corp. Accounts (Age 44)
- Mr. John Frederick Ek, Chief Financial Officer (Age 43)
- Mr. Eric Stier, Sr. VP, Gen. Counsel & Sec. (Age 43)
How do I buy shares of GenMark Diagnostics?
Shares of GNMK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is GenMark Diagnostics' stock price today?
One share of GNMK stock can currently be purchased for approximately $5.20.
How big of a company is GenMark Diagnostics?
GenMark Diagnostics has a market capitalization of $298.68 million and generates $70.76 million in revenue each year. The medical equipment provider earns $-50,500,000.00 in net income (profit) each year or ($0.91) on an earnings per share basis. GenMark Diagnostics employs 477 workers across the globe.View Additional Information About GenMark Diagnostics.
What is GenMark Diagnostics' official website?
How can I contact GenMark Diagnostics?
GenMark Diagnostics' mailing address is 5964 LA PLACE COURT, CARLSBAD CA, 92008. The medical equipment provider can be reached via phone at 760-448-4300 or via email at [email protected]
MarketBeat Community Rating for GenMark Diagnostics (NASDAQ GNMK)
MarketBeat's community ratings are surveys of what our community members think about GenMark Diagnostics and other stocks. Vote "Outperform" if you believe GNMK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GNMK will underperform the S&P 500 over the long term. You may vote once every thirty days.
